According to AZ, SERENA-6 is also the first pivotal trial to show the value of measuring circulating tumour DNA (ctDNA) to ...

PCOS, a prevalent hormonal disorder, poses challenges to conception, especially among young women. However, with early ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

Novartis announces phase III NATALEE trial of Kisqali reduces risk of recurrence in younger patients with early breast cancer: Basel Tuesday, June 3, 2025, 18:00 Hrs [IST] Novarti ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the Phase III INAVO120 study. These data showed ...

Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali(R) (ribociclib) plus endocrine therapy (ET, a non-steroidal ...

Switching to a new drug combination — camizestrant plus a CDK4/6 inhibitor — sooner may have positive results for advanced ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulve ...

The phase 3 SERENA-6 trial shows that ctDNA-guided early treatment switch to camizestrant plus a CDK4/6 inhibitor in HR+, ...

High testosterone in women can stem from conditions like PCOS and insulin resistance. Symptoms may include acne, excess hair ...

Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– ...